Matricelf Secures Title of Most Innovative Company at ATW26 in San Diego

Matricelf Triumphs at Advanced Therapies Week 2026

In a remarkable achievement for the biotechnology sector, Matricelf Ltd. (TASE: MTLF) has been recognized as the Most Innovative Company of 2026. The accolade was bestowed upon them during the Advanced Therapies Week (ATW26), a prestigious event held in San Diego, California, on March 2, 2026. This annual gathering stands out as a premier platform for biotechnology and pharmaceutical innovators, attracting over 1,800 participants from various industry sectors, including around 600 drug developers.

The Innovation Exchange Award, a significant highlight of the week, saw Matricelf claim first place amidst fierce competition. This award is particularly coveted, as it represents a recognition of extraordinary potential to impact patients' lives positively while also demonstrating notable commercial viability. Matricelf was chosen for its pioneering approach to spinal cord injury repair, which has progressed rapidly toward clinical application.

According to the judging panel, Matricelf’s nomination was compelling due to their innovative technology, which stands to make a meaningful difference in the treatment of spinal injuries. The recognition is emblematic of the strong performance of Israeli biotechnology on the global stage. Gil Hakim, CEO of Matricelf, described the honor as a defining moment not only for the company but for the entire Israeli biotech ecosystem. "This validation reinforces our potential and motivates us as we gear up for our pivotal 2026 milestone–a groundbreaking study involving human spinal injury patients."

The award gives Matricelf strategic visibility and opens doors for collaboration with leading investors and global partners. Such exposure is critical as the company continues its journey towards initiating the first clinical study of its kind aimed at restoring function to individuals affected by spinal cord injuries, a condition that affects millions worldwide.

Matricelf specializes in developing personalized, autologous regenerative therapies designed to carry out tissue repair. Their technology leverages proprietary hydrogel applications, enabling the creation of customized neural tissue implants that specifically target patients’ unique spinal injury situations. Originating at Tel Aviv University, this innovation is now being fully developed in Matricelf's facilities located in Ness Ziona, Israel.

As the world watches Matricelf's evolution, the company remains committed to advancing healthcare solutions that not only innovate but can ultimately provide hope to countless individuals living with paralysis. The milestone achieved at the ATW26 is only the beginning as Matricelf prepares to make significant contributions to regenerative medicine.

The journey ahead is marked by strategic efforts to finalize plans for the upcoming clinical trials, expected to initiate in the next few months. As Matricelf forges ahead, stakeholders can anticipate impactful results from their pioneering research that promises to redefine treatment paradigms in spinal cord injury therapies.

In conclusion, recognition at this year’s Advanced Therapies Week underscores Matricelf's role as a vanguard in regenerative medicine, solidifying their position as a leader in innovative healthcare solutions dedicated to improving lives.

Contact Information:
Gil Hakim
CEO, Matricelf
Tel: +972-52-5263351
Email: [email protected]